Antonio Passaro: Release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study

Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on LinkedIn:

”I am thrilled to announce the release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK translocations.

This editorial illuminates the significant milestones in the treatment of NSCLC with driver alterations. After the ADAURA, the ALINA study emerged as a beacon of hope, offering groundbreaking insights that redefine our approach to NSCLC treatment.

Let’s celebrate the journey of progress and innovation in NSCLC treatment. Together, let’s continue striving for excellence in patient care!

Dive into the full editorial in the NEJM and explore the complete manuscript of the ALINA study here. Share your reflections and perspectives as we navigate this transformative journey together.”

Source: Antonio Passaro/LinkedIn